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Abstract. Clinical trials designed to prevent type 1 diabetes (T1D) based on the autoimmunity paradigm have proved 
disappointing, and have not so far translated into patient benefit. Meanwhile, the incidence of T1D continues to rise. 
The accelerator hypothesis explores the role of weight gain in childhood diabetes, as both islet cell immunity and T1D 
are associated with BMI. Insulin resistance, which results largely from weight gain, increases insulin demand, and 
demand puts stress on beta cells, which accelerates their apoptotic loss. An immune response to the stress in those 
who are genetically predisposed (‘autoimmunity’) hastens the loss further, and may explain by default why 
autoimmunity is a feature of diabetes in the young. The accelerator hypothesis was proposed in 2001 and, like most 
hypothesis, has evolved over the years. 
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Himsworth was the first to describe insulin resistance in 
diabetes nearly 80 years ago but not, as is often thought, 
so as to distinguish adults from juveniles with the 
disease – insulin resistance was noted in both [1, 2]. 
Others repeated Himsworth’s observations using simple 
insulin-glucose tolerance tests [35], until a more 
sophisticated measure of insulin sensitivity, the glucose 
clamp, provided direct evidence that impaired insulin 
action is ‘…..a common feature of T1D’ [6]. Indeed, 
while conceding it was possible to separate patients 
according to insulin sensitivity, Elliott Joslin concluded 
that testing for it was of little use because the overlap in 
clinical phenotype was so great [7]. Insulin resistance 
was associated with diabetes from earliest times, in both 
young and old, and posed no threat to its oneness. 
The Categorisation of Diabetes 
Diabetes remained one until the 1970’s, when three 
observations made largely in children (lymphocytic 
insulitis [8], islet cell antibodies 9] and HLA genotype 
[10]) were interpreted by opinion leaders at the time to 
mean that childhood diabetes, unlike adult diabetes, was 
caused by dysregulation of the immune system 
(autoimmunity). A previously single disorder was now 
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deemed to be two categorically distinct entities of 
different aetiology, and the autoimmune paradigm has 
been deeply rooted since. Importantly, however, the 
classification was based on observation, and not on 
experiment. Indeed, some 20 human trials using 
immunotherapy to test the autoimmunity paradigm since 
have proved unsuccessful [11], and none has translated 
into patient benefit. Interest in the relationship of insulin 
resistance to autoimmunity emerged only because of 
mounting concern that the original interpretation may 
not have been correct [12]. Autoimmunity is clearly 
present in T1D, but its primacy in the sequence of 
events is being questioned. Rather than the driver of 
beta cell loss, could autoimmunity be an immune 
response to islets which are stressed by the demands of 
insulin resistance? 
Experimental Basis  
for Autoimmune Diabetes 
The experimental data cited in support of the autoimmunity 
hypothesis for T1D is substantial, but drawn largely 
from prevention studies in animals [13]. Such trials are 
often successful, but animals are not human, and 
biomedical research is frequently confronted with 
hypotheses that work in animals, but not in man. In the 
case of T1D, the models are not just animals, but animals 
abnormal to the point where they fail to develop diabetes 
unless their environment is rigidly controlled. The models 
most used, the NOD mouse and Biobreeding rat, are 
inbred for immununogenetic anomalies that are essential 
to the model, but not part of the human disease. The 
models show that the immune system can destroy the 
beta cells of inbred rodents, but say little about the 
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mechanisms responsible for T1D in outbred man. The 
ongoing TRIGR study using hydrolysed protein formula 
(Nutramigen) in human infants has an impressive 
pedigree, and will report in 2017, but care must be taken 
with confounders in its interpretation.  Nutramigen, like 
breast-milk, may be associated with slower growth rates 
than cow’s milk and breast-milk is associated with a 
lower incidence of T1D [14]. 
The Doctrine of Immunological Tolerance  
Any suggestion that autoimmunity might be a response 
to beta cell stress, rather than its cause, must first 
confront one of the pillars of immunology – tolerance to 
self antigens. The issue was addressed by the author 
some 25 years ago [15], in the wake of Pierre Grabar’s 
construal of the immune system’s primordial role as the 
body’s housekeeper, clearing up the detritus of 
apoptotic (and, where needed, necrotic) cell death [16]. 
Being shape-specific and clonal, the immune system 
was ideally adapted to expand and contract in response 
to specific housekeeping need. What to others before 
him had been a canon of absolute tolerance to self 
antigens, was to Grabar the absence of a technology 
sufficiently sensitive to detect a natural process of waste 
removal – until it was intense, when it was given the 
label ‘autoimmunity’ in order that it should comply with 
the tolerance paradigm [17]. Grabar’s great contribution 
was to breach the doctrine of self-tolerance that had 
previously obliged autoimmunity to be a pathology. 
Autoimmunity is nevertheless inflammatory, and may 
be expected to further accelerate apoptotic death of the 
troubled beta cell [18]. 
Orphan Observations  
‘Orphan observations’ are facts which don’t fit, and 
which tend to be ignored as a result. Concerns over the 
duality of diabetes first emerged through epidemiology, 
though few noted their significance at the time. 
Yemenite immigrants to Israel in the 1950’s suffered 
very little diabetes but, after 25 years in a land of plenty, 
experienced a 40-fold increase in its prevalence. 
Intriguingly, it wasn’t just T2D – the proportion of 
insulin dependency among the new diabetics was 
similar to that among Israelis of European origin [19]. 
The observation is a classic orphan, but fundamentally 
important because it suggests a common driver for both 
major forms of diabetes. Again, it is seldom remarked 
upon, but clearly documented, that wherever in the world 
there has been a rise in T2D, there has been a 
corresponding increase in type 1 [20], and many studies 
report how the frequency of T1D among the relatives of 
those with type 2 is many times greater than that in the 
general population [21, 22].
 
Most recently, Hussen et al 
report how having a parent with any type of diabetes 
increases the risk of T1D in the child [23].
 
 More 
fundamental still is the changing status of islet 
autoantibodies. Sero-positivity was always the exclusive 
hallmark of T1D, but reports of isle-related autoantibodies 
in people T2D have posed serious taxonomic difficulty 
[24]. Finally, there is now evidence for insulin resistance, 
not just in those with type 1 disease, but in those at-risk as 
well [2527]. When weighed together, orphan observations 
can shape a new paradigm, and the notion that T1D may be 
T2D accelerated into childhood by a reactive genotype is 
an example. 
The Accelerator Hypothesis 
Insulin resistance, largely (but not always) the result of 
excess weight gain, is generally believed to drive type 2 
diabetes. The metabolic up-regulation of the islets, and 
the glucotoxicity and lipotoxicity that result from the 
metabolic disturbance associated with insulin resistance, 
are thought to stress the beta cell and hasten its apoptosis 
[2830]. Excess weight gain is a feature of childhood over 
recent time, and it has been known for 40 years (though 
little mentioned) that children who develop T1D are on 
average heavier as toddlers than their peers who do not 
[31]. The observation resurfaced during the 1990’s 
[3234], and in 2001 the accelerator hypothesis formalised 
an alternative paradigm to autoimmunity – that Type 1 and 
type 2 diabetes are the same disorder of insulin resistance, 
set against different genetic backgrounds [35]. Beta cell 
stress, according to the hypothesis, provokes an immune 
response (autoimmunity) which is particularly intense in 
the small proportion of the population that carries reactive 
HLA genotypes, and a recent meta-analysis found in all the 
studies it reviewed that people with T1D showed greater 
weight gain during the first year of life compared with 
controls [36]. Crucially, if the immune reaction (the 
autoimmunity of T1D) is the response to beta cell stress, 
rather than the driver, it is arguably not the appropriate 
target for prevention. Evidence for the hypothesis has been 
set out in a number of reviews [3742], and its early 
predictions have held firm in several reports worldwide 
[4346],  though not in all [4749],  and for diverse reasons 
[5052]. The hypothesis anticipates that measures to 
reduce insulin demand will reduce the incidence of  
T1D but it does not dismiss autoimmunity. Rather, 
autoimmunity is regarded as a response to beta cell stress, 
not its cause, but inflammatory in its own right. The 
hypothesis is conceptually simple, but important if it resets 
the target for prevention of childhood diabetes from the 
immune system to insulin demand. 
Tempo – the Central Concept Underlying 
the Accelerator Hypothesis  
Diabetes is ultimately a disorder of beta cell loss [53], and 
the accelerator hypothesis is concerned with variation in 
the tempo of the loss. Beta cells are lost progressively over 
a lifetime [54], but the loss is of no consequence for most, 
given the substantial reserve [55]. However, if for 
whatever reason the loss is accelerated, it may become 
critical, and the age at presentation of diabetes will 
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depend on the degree of acceleration (Figure 1). Rather 
than categorise diabetes into types 1 and 2 (or indeed 
1½ [56],  LADA [57], hybrid [58], or double diabetes 
[59]), the accelerator hypothesis sees a continuous 
spectrum – a single process of beta cell loss which 
progresses at different rates, from ‘no’ diabetes during the 
lifetime of most people, through ‘slow’ diabetes in 
adulthood to ‘fast’ diabetes in childhood. The probability 
of developing diabetes is defined by an infinitely variable 
interaction between level of demand and immune response. 
The variation in diabetes is one of tempo, not of type. Only 
tempo can explain how T2D, that a generation ago was 
confined to middle age and beyond, has now become the 
fasting growing chronic disorder of childhood and how 
T1D, for decades a disorder of adolescence, is now rising 
fastest in the under 5’s [60]. 
Testing the Accelerator Hypothesis 
No evidence is complete without a randomized controlled 
trial, and no hypothesis is complete without a mechanism. 
If the accelerator hypothesis is to progress beyond 
speculation, it will be necessary to demonstrate that beta 
loss is slowed (and the incidence of T1D reduced) by 
protecting the beta cell against stress, and that beta cell 
rest is indeed the mechanism that drives the immune 
response that we call autoimmunity. Glucose is the 
principal stressor of the beta cell, and metformin is a 
recognized hypoglycaemic agent that is safe in children.  
The editor-in-chief of this journal was the first to test 
the ability of metformin to slow the progression of beta 
cell loss in a pilot study of 21 children recently diagnosed 
with T1D [61]. There were 26 control children on insulin 
alone. Six of the metformin-treated group entered complete 
insulin remission for 12 months or more, and their C-
peptide at the end of the study was significantly higher than 
that of the control group. It is not clear whether the 
metformin was simply re-sensitising the children to their 
own residual insulin, or preserving beta-cell function (the 
higher C-peptide might suggest true preservation), but the 
study provided impetus to the planning and ultimately 
funding by JDRF of the autoimmune diabetes Accelerator 
Prevention Trial (adAPT) currently recruiting in the UK. 
adAPT will expose children at high risk of T1D (double 
antibody positive) to metformin for five years in order to 
establish whether beta cell protection can reduce the 
incidence of diabetes. Mechanistic studies involving T 
cells (B. Roep, Leiden) will also seek to determine whether 
beta cell rest reduces immune reactivity to specific beta 
cell antigens.  
adAPT (Eudract # 2015-000748-41) is currently 
seeking youngsters throughout Scotland and the North 
of England who are the siblings or offspring age 5-16y 
of people who themselves developed T1D before the 
age of 25y. The 4-5% who are double antibody positive 
have a 40% chance of developing T1D over the course 
of the trial [62],  and will be invited to join a three stage 
randomised controlled trial of metformin. Stage 1 (four 
months, Pilot study) will validate the protocol, and 
establish the numbers that may ultimately be needed to 
achieve a reliable result. Stage 2 (36 months, Proof of 
principle) will indicate whether the rate of beta cell loss 
is slower in the treated group. C-peptide levels measured 
during the course of a multi-point mixed meal tolerance 
test will provide the outcome measure, but a subgroup 
will also be invited to participate in 7-day studies of 
continuous glucose monitoring. Stage 3 of adAPT (60 
months, T1D incidence) will compare the numbers who 
develop T1D in the active and placebo groups. adAPT 
will not report fully until 2022. 
adAPT is testing a new paradigm in type 1 diabetes. 
Where the immune activity in T1D has been looked upon 
previously as an immune attack by a dysregulated immune 
system, adAPT views it as a normal, if intense, response to 
beta cell stress caused by metabolic overload in people 
carrying a particular immunogenotype. A successful 
outcome to the trial may lead towards a safe, cheap and 
universally available approach to the prevention of type 1 
diabetes.   
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